BioSpace News Archive

Job Trends

AstraZeneca Rare Disease R&D Expansion Adds 500 Jobs At New Hub

On Rare Disease Day, Feburary 28, AstraZeneca announced the creation of the Alexion, AstraZeneca Rare Disease Development Hub in Toronto, Ontario.

February 28, 2023

·

2 min read

·

Tristan Manalac

Business

Economic Constriction has Fallout on Investments, IPOs and Collaborations

As the macro pressures of higher rates and fear of recession build, today’s investor is increasingly risk averse. With zero-risk options offering decent returns, only the highest-quality programs will get funding.

February 28, 2023

·

2 min read

·

Kate Goodwin

Peter Maag, Ph.D., James Chung, M.D., Ph.D./Kyver

Drug Development

Kyverna and Cabaletta are Repurposing CAR-T for Autoimmune Diseases

Researchers at Kyverna Therapeutics and Cabaletta Bio hope to repurpose CAR-T cell therapy for patients with autoimmune diseases.

February 28, 2023

·

3 min read

·

Hayley Shasteen

Drug Development

Theravance Cuts JAK Inhibitor, 17% of Workforce in Wake of Shareholder Letter

Theravance Biopharma is discontinuing research activities for its JAK inhibitor program in lung inflammation and reducing its headcount by about 17%.

February 28, 2023

·

2 min read

·

Tristan Manalac

Career Advice

What You Need to Know About Rage Applying

A variation of rage quitting, rage applying is a method of job searching that occurs when someone applies for many new roles while still employed in their current position.

February 28, 2023

·

3 min read

·

Franklin Carpenter

Career Advice

Career Advancement Tips for Pharmaceutical Sales Reps

Find out what it takes to become a successful pharma sales rep and discover helpful career advancement tips for pharmaceutical sales representatives.

February 28, 2023

·

5 min read

·

Don Potochny

Drug Development

Aptinyx’ Losing Streak Continues as Parkinson’s Candidate Falls Short

Aptinyx’s NYX-458 fell short of the primary endpoint in a Phase II trial of patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.

February 28, 2023

·

2 min read

·

Tristan Manalac

FDA

FDA Approves First Therapy for Friedreich’s Ataxia (Updated)

The FDA greenlit Reata Pharmaceuticals’ omaveloxolone (Skyclarys) as the first and only treatment for Friedreich’s ataxia, a rare, life-limiting neuromuscular disorder.

February 28, 2023

·

4 min read

·

Heather McKenzie

Oricell Closes $45M Series B1 Financing to Expand Development of Key Products

Oricell Therapeutics Co., Ltd (“Oricell” or “the Company”), a China-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics, today announced the close of a $45M Series B1 investment round after the completion of a $125M Series B fund-raise in July 2022.

February 28, 2023

·

6 min read

Biotech Bay

Cell and Gene Therapy Developers Are Worried About Clinical Holds From Inadequate Early Product Characterization, According to Mission Bio Survey

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced results of a new survey revealing persistent concerns by cell and gene therapy (CGT) developers over significant challenges to product characterization, despite rapid progress in the field.

February 28, 2023

·

4 min read